The effects of melatonin on liver functions in arsenic-induced liver damage

Turkish Journal of Surgery

Volumn 32, Issue 4, 2016, Pages 233-237

  Bali, Ilhan ^a   Bilir, Bülent ^a   Emir, Seyfi ^a   Turan, Filiz ^a   Yilmaz, Ahsen ^a   Gökkuş, Tuba ^a   Aydin, Murat ^a  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

Author keywords

Arsenic; Interleukin 6; Macrophage migration inhibitory factor; Melatonin; Monocyte chemotactic protein 1

Indexed keywords

EID: 85011003465     PISSN: 25646850     EISSN: 25647032     Source Type: Journal    
DOI: 10.5152/UCD.2015.3224     Document Type: Article

References (48)

1. Lombi E, Holm PE: Metalloids, soil chemistry and the environment. Adv Exp Med Biol 2010; 679: 33-44.
2. Wang P, Sun G, Jia Y, Meharg AA, Zhu Y. A review on completing arsenic biogeochemical cycle: microbial volatilization of arsines in environment. J Environ Sci 2014; 26: 371-381.
3. U.S. EPA, Arsenic Treatment Technologies for Soil, Waste and Water, U.S. EPA/National Service Center for Environmental Publications, Cincinnati, 2002.
4. P Mangalgiri, K, Adak A, Blaney L. Organoarsenicals in poultry litter: Detection, fate, and toxicity. Environ Int 2015; 75: 68-80.
5. Mandal BK, Suzuki KT. Arsenic round the world: a review. Talanta 2002; 58: 201-235.
6. Moore K. Treatment of arsenic contaminated groundwater using oxidation and membrane filtration, master of applied science in civil engineering, University of Waterloo, 2005.
7. Tchounwou PB, Wilson BA, Abdelghani AA, Ishaque AB, Patlolla A. Differential cytotoxicity and gene expression in human liver carcinoma (HepG2) cells exposed to arsenic trioxide and monosodium acid methanearsonate (MSMA). Int J Mol Sci 2002; 3: 1117-1132.
8. Fowler BA, Woods JS, Schiller CM. Ultrastructural and biochemical effects of prolonged oral arsenic exposure on liver mitochondria of rats. Environ Health Perspect 1977; 19: 197-204.
9. Bashir S, Sharma Y, Irshad M, Gupta SD, Dogra TD. Arsenic-induced cell death in liver and brain of experimental rats. Basic Clin Pharmacol Toxicol 2006; 98: 38-43.
10. Bashir S, Sharma Y, Irshad M, Nag TC, Tiwari M, Kabra M, et al. Arsenic induced apoptosis in rat liver following repeated 60 days exposure. Toxicology 2006; 217: 63-70.
11. Tosini G, Menaker M. The clock in the mouse retina: melatonin synthesis and photoreceptor degeneration. Brain Res 1998; 789: 221-228.
12. Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni JM. Evidence for melatonin synthesis in Mouse and human bone marrow cells. J Pineal Res 2000; 28: 193-202.
13. Slominski A, Tobin DJ, Zmijewski MA, Wortsman J, Paus R. Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol Metab 2008; 19: 17-24.
14. Champier J, Claustrat B, Besançon R, Eymin C, Killer C, Jouvet A, et al. Evidence for tryptophan hydroxylase and hydroxy-indol-O-methyl-transferase mRNAs in human blood platelets. Life Sci 1997; 60: 2191-2197.
15. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, García-Maurio S, Reiter RJ, et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004; 18: 537-539.
16. Tijmes M, Pedraza R, Valladares L. Melatonin in the rat testis: evidence for local synthesis. Steroids 1996; 61: 65-68.
17. Bubenik GA: Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47: 2336-2348.
18. Reiter RJ, Tan DX. Melatonin: A novel protective agent against oxidative injury of the ischemic-reperfused heart. Cardiovasc Res 2003; 58: 10-19.
19. Cruz MH, Leal CL, Cruz JF, Tan DX, Reiter RJ. Essential actions of melatonin in protecting the ovary from oxidative damage. Theriogenology 2014; 82: 925-932.
20. Reiter DJ, Tan DX, Kim SJ, Wenbo QI. Melatonin as a pharmacological agent against oxidative damage to lipids and DNA. Proc West Pharmacol Soc 1998; 41: 229-236.
21. Reiter R, Garcia JJ, Tang L, Munoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci 1997; 60: 2255-2257.
22. Çaǧlikülekçi M, Bilgin Ö, Canbaz H, Dirlik M, Baǧdatoǧlu Ö, Üstünsoy B, ve ark. Deneysel hepatik iskemi reperfüzyon modelinde melatonin uygulamasinin kan ve karaciǧer doku lipid peroksidasyonuna etkisi. Ulus Cerrahi Derg 2006; 22: 93-98.
23. Costa EJ, Shida CS, Biaggi MH, Ito AS, Lamy-Freund MT. How melatonin interacts with lipid bilayers: A study by fluorescence and ESR spectroscopies. F.E.B.S. Lett 1997; 416: 103-106.
24. Cuesta S, Kireev R, Forman K, García C, Escames G, Ariznavarreta C, et al. Experimental Gerontology Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8) Exp Gerontol 2010; 45: 950-956.
25. Shin IS, Park JW, Shin NR, Jeon CM, Kwon OK, Kim JS, et al. Melatonin reduces airway inflammation in ovalbumin-induced asthma. Immunobiology 2014; 219: 901-908.
26. Da Rosa DP, Forgiarini LF, e Silva MB, Fiori CZ, Andrade CF, Martinez D, et al. Antioxidants inhibit the inflammatory and apoptotic processes in an intermittent hypoxia model of sleep apnea. Inflamm Res 2015; 64: 21-29.
27. Wang L, Kou MC, Weng CY, Hu LW, Wang YJ, Wu MJ. Arsenic modulates heme oxygenase-1, interleukin-6, and vascular endothelial growth factor expression in endothelial cells: roles of ROS, NF-κB, and MAPK pathways. Arch Toxicol 2012; 86: 879-896.
28. Sumedha N, Miltonprabu S. Diallyl trisulfide ameliorates arsenic-induced hepatotoxicity by abrogation of oxidative stress, inflammation, and apoptosis in rats. Hum Exp Toxicol 2014; pii: 0960327114543933.
29. Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336: 186-195.
30. Pal S, Chatterjee AK. Possible beneficial effects of melatonin supplementation on arsenic-induced oxidative stress in Wistar rats. Drug Chem Toxicol 2006; 29: 423-433.
31. Sigala F, Theocharis S, Sigalas K, Markantonis-Kyroudis S, Papalabros E, Triantafyllou A, et al. Therapeutic value of melatonin in an experimental model of liver injury and regeneration. J Pineal Res 2006; 40: 270-279.
32. Ohta Y, Kongo M, Sasaki E, Nishida K, Ishiguro I. Therapeutic effect of melatonin on carbon tetrachloride-induced acute liver injury in rats. J Pineal Res 2000; 28: 119-126.
33. Wroblewski F, Ladue JS. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med 1956; 91: 569-571.
34. Sette LH, Almeida Lopes EP. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review. Clinics 2014; 69: 271-278.
35. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005; 172: 367-379.
36. Liu J, Waalkes M P. Liver is a target of arsenic carcinogenesis. Toxicol Sci 2008; 105: 24-32.
37. Kus I, Ogeturk M, Oner H, Sahin S, Yekeler H, Sarsilmaz M. Protective effects of melatonin against carbon tetrachlorideinduced hepatotoxicity in rats: a light microscopic and biochemical study. Cell Biochem Funct 2005; 23: 169-174.
38. Jung KH, Hong SW, Zheng HM, Lee DH, Hong SS. Melatonin down-regulates nuclear erythroid 2-related factor 2 and nuclear factor-kappaB during prevention of oxidative liver injury in a dimethylnitrosamine model. J Pineal Res 2009; 47: 173-183.
39. Sener G, Sehirli AO, Ayanoǧlu-Dülger G. Protective effects of melatonin, vitamin E and N-acetylcysteine against acetaminophen toxicity in mice: a comparative study. J Pineal Res 2003; 35: 61-68.
40. Karadaǧ R, Koca C, Totan Y, Yaǧci R, Aydin M, Karadaǧ AS, et al. Comparison Of Serum Levels Of Il-6, Il-8, Tnf-A, C Reactive Protein And Heat Shock Protein 70 İn Patients With Active or İnactive Behçet's Disease. Turk J Med Sci 2010; 40: 57-62.
41. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 2008; 7: 189-203.
42. Broncel M, Koziróg-Kołacińska M, Chojnowska-Jezierska J. Melatonin in the treatment of atherosclerosis. Pol Merkur Lekarski 2007; 23: 124-127.
43. Kesavan M, Sarath TS, Kannan K, Suresh S, Gupta P, Vijayakaran K, et al. Atorvastatin restores arsenic-induced vascular dysfunction in rats: modulation of nitric oxide signaling and inflammatory mediators. Toxicol Appl Pharmacol 2014; 280: 107-116.
44. Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med 2002; 30: 27-35.
45. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002; 4: 449-460.
46. Kobayashi S, Nishihira J, Watanabe S, Todo S. Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide. Hepatology 1999; 29: 1752-1759.
47. Bourdi M, Reilly TP, Elkahloun AG, George JW, Pohl LR. Macrophage migration inhibitory factor in drug-induced liver injury: a role in susceptibility and stress responsivenessq. Biochem Biophys Res Commun 2002; 294: 225-230.
48. Hoi AY, Iskander MN, Morand EF. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm Allergy Drug Targets 2007; 6: 183-190.